Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nexavar Expansion Plans Suffer Another Blow With Failed Phase III Lung Cancer Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.

You may also be interested in...



Another Attempt To Expand Nexavar Label Ends In Disappointment

Bayer/Amgen’s Nexavar fails to improve progression-free survival in a Phase III HER2-negative breast cancer study. Approved indications are not affected, the companies note.

R&D Productivity Still Lags: Study Shows Success Rates May Have Been Overestimated

Large study tracking drug indications pursued by more than 800 companies over almost a decade finds that only one in 10 wound up getting approved. By therapeutic area, Phase III success rates were lowest in cancer and cardiovascular medicine, and highest in diabetes, infectious and autoimmune disease.

Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy

Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel